UK Authorization for Aflibercept   - Takeaways - MDSpire

UK Authorization for Aflibercept  

MHRA clears Eylea for macular edema following retinal vein occlusion

  • March 3, 2026

  • 2 min

Share

  • 1

    The UK MHRA has authorized aflibercept 8 mg for treating visual impairment due to retinal vein occlusion.

  • 2

    This approval is based on the Phase III QUASAR trial, demonstrating non-inferior visual acuity gains compared to aflibercept 2 mg.

  • 3

    Patients receiving aflibercept 8 mg required fewer injections on average than those receiving the 2 mg formulation.

  • 4

    Over 60% of patients in the 8 mg group achieved treatment intervals of four months or longer by week 64.

  • 5

    The authorization aims to reduce injection burden while maintaining visual outcomes for patients with RVO.

Original Source(s)

UK Authorization for Aflibercept  

  • March 3, 2026

Related Content

Survey: 96% of Optometrists Assess Smoking Status

Survey finds widespread smoking status screening among optometrists in Wales following national training requirements.

Atsena Reports LIGHTHOUSE data at ARVO

Atsena Therapeutics announced positive clinical data results from Part A of the LIGHTHOUSE study, a phase 1/2 clinical trial evaluating subretinal injection of ATSN-201 for the treatment of X-linked retinoschisis (XLRS). The data were presented at the 2025 Association for Research in Vision and Ophthalmology meeting in Salt Lake City, Utah.

  • May 1, 2025

  • 3 min
Can Oral Gildeuretinol Slow Advanced Macular Degeneration?

Although the trial missed its primary endpoint, exploratory analyses suggested slower lesion growth and better functional outcomes with gildeuretinol.